Jakavi™ (ruxoltinib phosphate) 5mg, 10mg, 15mg and 20mg is a prescription medicine available as tablets for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Jakavi is a funded medicine, criteria apply. Normal doctor visit fees apply. Ask your doctor if Jakavi is right for you. Use strictly as directed. Always take Jakavi exactly as your doctor has told you and tell your doctor or pharmacist if you are taking any other medicines, or if you start new ones. Take Jakavi twice a day, every day, at about the same time each day. Avoid becoming pregnant or breast feeding while taking Jakavi. Jakavi has risks and benefits. The most common side effects include bruising, dizziness, headaches, constipation, feeling tired, infections, fever, chills, sore throat, mouth ulcers, nausea, high blood pressure and pale skin. The more serious side effects include urinary tract and other serious infections, shingles, bruising more easily, blood disorders and trouble breathing. These may require urgent medical attention. Tell your doctor or pharmacist if you notice anything else that worries you or that may be making you feel unwell. For more information, including what to do if you have any side effects, see the full CMI (available at www.medsafe.govt.nz ). Jakavi is the registered trademark of Novartis AG. Novartis New Zealand Ltd, Auckland Ph 0800 652 422.

IMPORTANT: This stock card is for non-funded Jakavi™ only. If you have a Special Authority for Jakavi™, please contact our team to discuss prescription fulfillment.